DepoMed Inc

Most Recent

  • uploads///DEPO
    Company & Industry Overviews

    Behind Depomed’s Business Strategy

    Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow.

    By Kenneth Smith
  • uploads///thermometer _
    Company & Industry Overviews

    Depomed versus Peers in March 2018: Analyst Ratings

    Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions.

    By Kenneth Smith
  • uploads///cara pipeline Jan
    Company & Industry Overviews

    A Look at Cara Therapeutics’ Intravenous CR845

    Intravenous CR845 for pruritus Pruritus is associated with chronic conditions such as chronic kidney disease (or CKD), atopic dermatitis, eczema, cholestatic liver disease, and psoriasis. Based on CR845’s effectiveness on the peripheral nervous system and immune cells, as well as its anti-pruritic potency, Cara Therapeutics (CARA) believes the drug has the potential to treat pruritus […]

    By Kenneth Smith
  • uploads///Chart  Consumer
    Earnings Report

    How GlaxoSmithKline’s Consumer Healthcare Segment Fared in 1Q17

    With improvements in the supply chain and the successful launch of new products, GlaxoSmithKline (GSK) is optimistic about its consumer healthcare segment performance in coming years.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at GlaxoSmithKline’s Consumer Healthcare Business

    Following improvements in its supply chain and its successful launch of new products, GlaxoSmithKline is optimistic about its Consumer Healthcare segment.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GSK Optimistic about Future of Its Consumer Healthcare Segment

    With improvements in the supply chain and successful launch of new products, GlaxoSmithKline (GSK) is optimistic about its consumer healthcare segment performance.

    By Mike Benson
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Horizon Rose and Outperformed IBB’s Mid-Cap Stocks

    Horizon Pharma rose 5.4% on November 16, 2015. The stock rose due to the update at the shareholder meeting regarding the Depomed acquisition.

    By Peter Neil
  • uploads///Chart
    Macroeconomic Analysis

    PJP and PBE Are Sectoral Smart Beta Funds

    The PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP) is a smart beta fund that tracks the performance of the Dynamic Pharmaceutical Intellidex Index.

    By Ivan Kading
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.